Stay updated with breaking news from Floor Effect. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Path forward for ALS is a registrational Phase 3b U.S. clinical trial - - Biologics License Application to be withdrawn without prejudice - - Conference call and webcast at 8:30am ET today...
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today...
FDA advisory committee meeting to discuss NurOwn® for Amyotrophic Lateral Sclerosis scheduled for September 27, 2023 BrainStorm's Biologics License Application for NurOwn has a Prescription... -Today at 07:06 am- MarketScreener
/PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, this week...